Literature DB >> 16831851

Second consensus on medical treatment of metastatic breast cancer.

S Beslija1, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W J Köstler, M Krainer, S Menard, T Petit, L Petruzelka, K Possinger, P Schmid, E Stadtmauer, M Stockler, S Van Belle, C Vogel, N Wilcken, C Wiltschke, C C Zielinski, H Zwierzina.   

Abstract

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

Entities:  

Mesh:

Year:  2006        PMID: 16831851     DOI: 10.1093/annonc/mdl155

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  24 in total

1.  More options, more considerations: how new treatment options influence clinical decision making.

Authors:  In Hae Park
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 2.  Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.

Authors:  Michael Gnant; Richard Greil; Michael Hubalek; Günther Steger
Journal:  Breast Care (Basel)       Date:  2013-08       Impact factor: 2.860

3.  Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.

Authors:  Guenther G Steger; Jitka Abrahámová; Florin Bacanu; Stephen Brincat; Arija Brize; Alvydas Cesas; Tanja Cufer; Magdolna Dank; Renata Duchnowska; Alexandru Eniu; Jacek Jassem; Zsuzsanna Kahán; Erika Matos; Peeter Padrik; Signe Plāte; Helis Pokker; Gunta Purkalne; Constanta Timcheva; Valentina Tzekova; Rostislav Vyzula; Christoph C Zielinski
Journal:  Wien Klin Wochenschr       Date:  2010-06-15       Impact factor: 1.704

4.  Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

Authors:  Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2010-04-26

5.  Radiofrequency ablation of metastatic lesions from breast cancer.

Authors:  C Bortolotto; S Macchi; L Veronese; R Dore; F Draghi; S Rossi
Journal:  J Ultrasound       Date:  2012-06-27

6.  Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.

Authors:  Mu-Tai Liu; Wen-Tao Huang; Ai-Yih Wang; Chia-Chun Huang; Chao-Yuan Huang; Tung-Hao Chang; Chu-Pin Pi; Hao-Han Yang
Journal:  Support Care Cancer       Date:  2009-11-11       Impact factor: 3.603

7.  Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Authors:  Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Optimal use of taxanes in metastatic breast cancer.

Authors:  K M King; S Lupichuk; L Baig; M Webster; S Basi; D Whyte; S Rix
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

Review 9.  International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Authors:  Fatima Cardoso; Philippe L Bedard; Eric P Winer; Olivia Pagani; Elzbieta Senkus-Konefka; Lesley J Fallowfield; Stella Kyriakides; Alberto Costa; Tanja Cufer; Kathy S Albain
Journal:  J Natl Cancer Inst       Date:  2009-08-05       Impact factor: 13.506

10.  Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

Authors:  David W Miles
Journal:  Breast Cancer Res       Date:  2009-08-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.